More Than 700 Medicines Face Shortages Across Switzerland

More than 700 medicines are currently listed as affected by supply bottlenecks in Switzerland. The figure comes from drugshortage.ch, a monitoring platform established by Enea Martinelli, a hospital pharmacist. Its list covers individual medicine packs and reaches beyond the narrower range monitored by federal authorities.

The disruption affects products used in hospitals, pharmacies and other parts of the health-care system. A separate analysis of the platform identified 67 medicines containing 42 distinct active ingredients whose shortages are classified as critical or very critical. The list includes treatments for cancer, infections, eye conditions, blood disorders, neurology, pain, heart disease and addiction.

The timing has given the issue fresh political weight. The National Council debated Martinelli’s popular initiative, Yes to the Security of Medical Care, during the week covered by the report. The proposal would require the federal government to take stronger action to secure medicine supplies. A broad coalition from the health-care sector supports it, while the Federal Council has offered a direct counter-proposal.

Switzerland now faces a parliamentary debate over how far the state should go in managing a supply chain that can fail far beyond the country’s borders.

Cancer treatment accounts for 10 of the active ingredients in the critical and very critical shortage group. Infections, eye conditions and blood disorders each account for five active ingredients, while neurology accounts for four. Other affected areas include pain relief, heart disease, addiction treatment, psychiatry, endocrinology, obstetrics, anaesthesia and supportive care.

These figures describe active ingredients, not a count of every affected package. The distinction matters because several medicine packs can contain the same active ingredient, while one treatment area may depend on multiple products. The broader platform records more than 700 individual medicines facing bottlenecks, whereas the critical analysis isolates the most serious cases.

For patients and clinicians, a shortage can require a substitution, a change in dosage form or a search for stock at another provider. The source report does not give a breakdown by canton or quantify delays for individual patients. It does show that the problem reaches across treatment areas, from oncology to antibiotics and blood care.

The concentration of critical cases in medicines used for serious illnesses places particular importance on advance planning. Hospitals and pharmacies must track availability while clinicians consider medically suitable alternatives.

The Swiss monitoring system does not cover every medicine in the same way. Federal authorities collect information on shortages and interruptions, but their monitoring focuses mainly on medicines classified as essential. Martinelli created drugshortage.ch because he considered that approach too narrow.

The platform draws much of its information from pharmaceutical companies and from a wholesaler supplying health-care providers. It tracks shortages of individual packs and casts a wider net than the official system. That produces a larger view of the market, while also reflecting the practical difficulty of defining when a product is unavailable, difficult to obtain or replaceable by another pack.

The source report does not establish that every listing represents a complete national stockout. It reports supply bottlenecks and identifies a smaller group as critical or very critical. That distinction is important for patients, pharmacists and policymakers assessing the scale of the problem.

The competing monitoring approaches have also shaped the political debate. Supporters of stronger federal action point to the need for a fuller picture of availability. The government’s counter-proposal seeks a more targeted response. Parliament must now decide how much information the state should gather and how it should act on it.